TITLE

Expression and Biological Significance of Leptin, Leptin Receptor, VEGF, and CD34 in Colorectal Carcinoma

AUTHOR(S)
Liu Hui; Wan Desen; Pan Zhizhong; Cao Lijing; Wu Xiaojun; Lu Zhenhai; Kang Tai
PUB. DATE
July 2011
SOURCE
Cell Biochemistry & Biophysics;Jul2011, Vol. 60 Issue 3, p241
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
To investigate the expression and biological significance of Leptin, Leptin receptor, Vascular Endothelial Growth Factor (VEGF), and CD34 protein in colorectal carcinoma tissues. The expression of Leptin, Leptin receptor, VEGF, and CD34 was detected in 68 cases of colorectal carcinoma tissues, paired para-carcinoma tissues and normal colorectal tissues by Immunohistochemical SP Method. The results and related clinicopathological data were analyzed. The positive rate of Leptin, Leptin receptor, and VEGF was significantly higher in colorectal carcinoma tissues than that in paired para-carcinoma tissues and normal colorectal tissues. The expression of Leptin, Leptin receptor, and VEGF was correlated with grade of tumor differentiation, depth of bowel wall invasion, lymph node metastasis, Dukes stage, distant metastasis, and lympho/vascular tumor embolization. Microvessel density (MVD) value in colorectal carcinoma was significantly higher than that in para-carcinoma tissues and normal colorectal tissues, and the density in para-carcinoma tissues was higher than that in normal colorectal tissues. The expression of Leptin, Leptin receptor, VEGF, and MVD value in colorectal carcinoma was positively correlated. In conclusion, microvessel density value is an important index of the growth, invasion, and metastasis of colorectal carcinoma. The binding of Leptin and Leptin receptor promotes the proliferation of colorectal carcinoma cells. The synergy between Leptin and VEGF accelerates the angiogenesis in colorectal carcinoma and accelerates the invasion and metastasis of the tumor cells.
ACCESSION #
61190748

 

Related Articles

  • miRNA-27b Targets Vascular Endothelial Growth Factor C to Inhibit Tumor Progression and Angiogenesis in Colorectal Cancer. Ye, Jun; Wu, Xianguo; Wu, Dang; Wu, Pin; Ni, Chao; Zhang, Zhigang; Chen, Zhigang; Qiu, Fuming; Xu, Jinghong; Huang, Jian // PLoS ONE;Apr2013, Vol. 8 Issue 4, p1 

    Colorectal cancer (CRC) is one of the most prevalent cancers globally and is one of the leading causes of cancer-related deaths due to therapy resistance and metastasis. Understanding the mechanism underlying colorectal carcinogenesis is essential for the diagnosis and treatment of CRC....

  • Vascular Endothelial Growth Factor Receptor-2 Couples Cyclo-Oxygenase-2 with Pro-Angiogenic Actions of Leptin on Human Endothelial Cells. Garonna, Elena; Botham, Kathleen M.; Birdsey, Graeme M.; Randi, Anna M.; Gonzalez-Perez, Ruben R.; Wheeler-Jones, Caroline P. D. // PLoS ONE;2011, Vol. 6 Issue 4, p1 

    Background: The adipocyte-derived hormone leptin influences the behaviour of a wide range of cell types and is now recognised as a pro-angiogenic and pro-inflammatory factor. In the vasculature, these effects are mediated in part through its direct leptin receptor (ObRb)-driven actions on...

  • Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Fan, Fan; Wey, Jane S; McCarty, Marya F; Belcheva, Anna; Liu, Wenbiao; Bauer, Todd W; Somcio, Ray J; Wu, Yan; Hooper, Andrea; Hicklin, Daniel J; Ellis, Lee M // Oncogene;4/14/2005, Vol. 24 Issue 16, p2647 

    Vascular endothelial growth factor (VEGF) is associated with tumor angiogenesis and poor prognosis in human colorectal cancer (CRC). VEGF receptor-1 (VEGFR-1 or Flt-1) is a high-affinity receptor for VEGF and is typically considered specific to endothelial cells. Here we report the expression...

  • Factors Influencing Tissue Concentration of Vascular Endothelial Growth Factor in Colorectal Carcinoma. Ono, Taku; Miki, Chikao // American Journal of Gastroenterology;Apr2000, Vol. 95 Issue 4, p1062 

    OBJECTIVE: Vascular endothelial growth factor (VEGF) promotes proliferation of various tumor cells by stimulating angiogenesis. Experimentally, hypoxia and energy depletion are known to induce angiogenesis by increasing VEGF expression. We investigated whether factors reflecting the general...

  • Vascular endothelial growth factor in colorectal cancer. Guba, Markus; Seeliger, Hendrik; Kleespies, Axel; Jauch, Karl-Walter; Bruns, Christiane // International Journal of Colorectal Disease;Nov2004, Vol. 19 Issue 6, p510 

    Background: Angiogenesis plays an important role in colorectal cancer progression. Evidence from preclinical and clinical studies indicates that vascular endothelial growth factor (VEGF) is the predominant angiogenic factor in human colorectal cancer and is associated with formation of...

  • Vascular endothelial growth factor and endoglin expression in colorectal cancer. Dassoulas, Konstantinos; Gazouli, Maria; Theodoropoulos, George; Christoni, Zoi; Rizos, Spyros; Zisi-Serbetzoglou, Adamantia; Glava, Chrissa; Karantanos, Theodoros; Klonaris, Christos; Karakitsos, Petros // Journal of Cancer Research & Clinical Oncology;May2010, Vol. 136 Issue 5, p703 

    Vascular endothelial growth factor (VEGF) overexpression has been associated with advanced stage and poor survival in several cancers. Additionally, endoglin was proposed as a marker of neovascularization in solid malignancies. The aim of this study was to evaluate the association between the...

  • Oncology Nursing in a New Era: Optimizing Treatment With Bevacizumab. Marrs, Joyce; Zubal, Beth A. // Clinical Journal of Oncology Nursing;Oct2009, Vol. 13 Issue 5, p564 

    Overexpression of vascular endothelial growth factor (VEGF) by tumor cells promotes angiogenesis, which correlates with progressive tumor growth and poor outcomes in many types of cancer. Bevacizumab inhibits VEGF to promote regression of tumor vessels by limiting blood supply and tumor growth,...

  • Managing patients with metastatic colorectal cancer on bevacizumab. Lemmens, Liesbeth; Claes, Viviane; Uzzell, Maggie // British Journal of Nursing;8/14/2008, Vol. 17 Issue 15, p944 

    Bevacizumab (Avastin®) is a humanized monoclonal antibody that inhibits the activity of vascular endothelial growth factor (VEGF), a key molecule controlling tumour blood vessel formation (angiogenesis). By inhibiting VEGF and thus tumour angiogenesis, bevacizumab inhibits tumour growth and...

  • Vascular Endothelial Growth Factors C and D Represent Novel Prognostic Markers in Colorectal Carcinoma Using Quantitative Image Analysis. W.-G. Hu; J.-W. Li; B. Feng; M. Beveridge; F. Yue; A. -G. Lu; J. -J. Ma; M. -L. Wang; Y. Guo; X.-J. Jin; M.-H. Zheng // European Surgical Research;2007, Vol. 39 Issue 4, p229 

    Background/Aims: Vascular endothelial growth factor C (VEGF-C) and vascular endothelial growth factor D (VEGF-D) are potent lymphangiogenic and angiogenetic mediators in many kinds of tumors. However, the exact impacts of VEGF-C and VEGF-D on the prognosis of colorectal cancer (CRC) remain...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics